Already under scrutiny from lawmakers over pricing of its EpiPen epinephrine injector, Mylan faces new lawsuits from consumers and a competitor in New Jersey federal courts accusing it of taking anti-competitive actions to protect its product’s market share.
Sanofi-Aventis U.S. sued Mylan on April 24, seeking reimbursement for lost sales of its competing product. And Mylan was sued on April 7 on behalf of a putative class of consumers who accuse the company of conspiring with others to eliminate competition for the EpiPen. Both suits assert that Mylan paid bonuses to insurance companies, benefit managers and other third-party payors if they refused to reimburse users of competing products, including Auvi-Q, an epinephrine injector introduced by Sanofi in 2013.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
